DZIP1 expressed in fibroblasts and tumor cells may affect immunosuppression and metastatic potential in gastric cancer
International Immunopharmacology · 2023-04 · 117 · 109886
DOI: 10.1016/j.intimp.2023.109886 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023-04. Verfasst von Yi Yin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Hospital of Nanjing the University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing 210023, Jiangsu Province, C…. Hauptthemen laut MEDLINE: Stomach Neoplasms, Cancer-Associated Fibroblasts. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Jiangsu Province People's Government, Jiangsu Science and Technology Department.
Abstract (Originalsprache)
The tumor microenvironment (TME) contains complex components, of which the most well-known one is the tumor-associated fibroblast (CAF) that participates in the development and progression of tumors. A high abundance of CAFs implies that tumor stroma is also abundant and often predicts a poor prognosis, especially in terms of immunotherapeutic resistance. In this study, DAZ interacting zinc finger protein 1 (DZIP1) was identified to be upregulated in CAFs and malignant epithelial cells based on single-cell sequencing. Furthermore, results from The Cancer Genome Atlas database showed that this gene was highly positively associated with the mesenchymal phenotype in gastric cancer (GC). In addition, molecular experiments verified that DZIP1 directly promoted the proliferation of CAFs and enhanced the epithelial-mesenchymal transition (EMT) of GC cells to drive angiogenesis. Also, the upregulated DZIP1 in GC cells was found to directly promote invasion and metastasis. Finally, multiplex immunofluorescence and immunohistochemistry showed that DZIP1 was correlated with the immunosuppressive microenvironment of GC and resulted in a poor response to immunotherapy. Overall, our findings suggest that DZIP1 is expressed in both tumor parenchyma and mesenchyme and that it is involved in shaping the immunosuppressive microenvironment and inducing EMT by participating in tumor-stromal signaling crosstalk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Affiliated Hospital of Nanjing the University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing 210023, Jiangsu Province, China; No. 1 Clinical Medical College, Nanjing University of Chinese Me…
- Affiliated Hospital of Nanjing the University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing 210023, Jiangsu Province, China.
- Hunan Aifang Biological Company Limited, Changsha 410000, Hunan Province, China.
Förderung
- National Natural Science Foundation of China
- Jiangsu Province People's Government
- Jiangsu Science and Technology Department
Zitieren
APA
Yin, Y., Liu, Y., Wang, Y., Li, J., Liang, S., Zhang, W., Ma, Z., Liu, S., & Zou, X. (2023). DZIP1 expressed in fibroblasts and tumor cells may affect immunosuppression and metastatic potential in gastric cancer. International Immunopharmacology, 117, 109886. https://doi.org/10.1016/j.intimp.2023.109886
Vancouver
Yin Y, Liu Y, Wang Y, Li J, Liang S, Zhang W, et al. DZIP1 expressed in fibroblasts and tumor cells may affect immunosuppression and metastatic potential in gastric cancer. International Immunopharmacology. 2023;117:109886. doi:10.1016/j.intimp.2023.109886
BibTeX
@article{Yin2023,
author = {Yin, Yi and Liu, Yuanjie and Wang, Yunya and Li, Jiepin and Liang, Shuo and Zhang, Wei and Ma, Zhibin and Liu, Shenlin and Zou, Xi},
title = {DZIP1 expressed in fibroblasts and tumor cells may affect immunosuppression and metastatic potential in gastric cancer},
journal = {International Immunopharmacology},
year = {2023},
volume = {117},
pages = {109886},
doi = {10.1016/j.intimp.2023.109886}
}
EUVIMED